Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 2.38B P/E - EPS this Y -37.50% Ern Qtrly Grth -
Income -113.56M Forward P/E -192.15 EPS next Y 93.80% 50D Avg Chg 31.00%
Sales 12.89M PEG - EPS past 5Y - 200D Avg Chg 146.00%
Dividend N/A Price/Book 17.97 EPS next 5Y - 52W High Chg -
Recommedations 2.00 Quick Ratio 1.84 Shares Outstanding 91.10M 52W Low Chg 684.00%
Insider Own 4.62% ROA -43.01% Shares Float 69.61M Beta 2.46
Inst Own 53.26% ROE -97.66% Shares Shorted/Prior 5.88M/8.20M Price 24.98
Gross Margin - Profit Margin - Avg. Volume 2,842,990 Target Price 23.50
Oper. Margin -993.88% Earnings Date Aug 2 Volume 9,124,151 Change 0.00%
About Provention Bio, Inc.

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.

PRVB Chatroom

User Image yilongma2024 Posted - 11 hours ago

$AKBA hope this is not the next $GMDA or $MCRB! Instead, $PRVB.

User Image BigElvis_GTown Posted - 1 day ago

$ALT LT gains for me after August. The data is still good. Maybe a little disappointed but I went through this with $PRVB too and that paid off in the end.

User Image CharlesEscobar Posted - 3 days ago

$PRVB Was my big play last year $KRON Will be my big play for 2024/2025 $NTLA Still the holy grail biopharma opportunity for the next decade...

User Image jrmora71 Posted - 1 week ago

$MCRB In contrasts to $PRVB and $IBRX that have been very rewarding in my portfolio, $MCRB has been consistently my worst investment. Since May last yearI I had substantial losses, which I fortunately couldleverage for tax harvesting in Dec. However, I gave it another chance in Jan when I thought it could not deep-dive below $1…But you see what keeps happening, so finally I decided to leave this position for good. Good luck to all longs that will remain here; hopefully you will get rewarded or at least recover some of your losses.

User Image StillnessofBreath Posted - 2 weeks ago

$MCRB shares are being stolen! https://link.springer.com/article/10.1007/s40265-024-02006-7 Everyone loves to say ATM, but no one has a clue,ostensibly don’t read 10q 1. If atm, still super undervalued, at least you aren’t buying at $5 Either way this is more like $CCXI $PRVB where they dropped heavily after approval to accumulate before buyout announcement

User Image trf07 Posted - 3 weeks ago

$CELZ Know what you hold. $PRVB was into T1 Diabetes therapy also and was bought at 2.9 billion $. $SGTX also early stage T1 Diabetes therapy was bought for more than 300 milliy$. CELZ mcap currently 9 mill. 😎

User Image trf07 Posted - 3 weeks ago

$CELZ this is being manipulated. You will regret it if you sell. It is a multi-day runner. Look what happened to $PRVB

User Image Kingjake26 Posted - 3 weeks ago

$BTTX The breakthrough status is reserved for technologies that show the potential to be more effective than the existing standard of care in patients with serious or life-threatening conditions, Better Therapeutics said. $PRVB These guys got bought out. I can see the big pharma wanting to add this to their portfolio. $XBI

User Image initfortheride Posted - 3 weeks ago

@MajorFate I bought $PRVB down to $1.70 and eventually waited it out, but they were able to communicate continued progress and eventually a drawn out PDUFA process, but kept delivering.

User Image Kingjake26 Posted - 3 weeks ago

@LetMeBuy I have a big company will want this one. Who ever bought it $PRVB will have there eyes on this on. $XBI

User Image MajorFate Posted - 3 weeks ago

$PRVB I feel as though Sanofi got away with this one for cheap

User Image DrScoob Posted - 3 weeks ago

I’ve concluded the juice has been squeezed here. Moving $PRVB gains to $ANVS and $IOVA for greater potential upside.

User Image DrScoob Posted - 3 weeks ago

@papatrick @ForestFoxes $PRVB had PK issues. In the case of ANVS Low levels of drug in plasma for Parkinson’s is often because patients didn’t follow their dose regime which is common for this disease. So if it’s only 40 patients it is not a big deal. Is bullish actually

User Image DrScoob Posted - 1 month ago

$ANVS Knowing Maria, & her being candid and transparent tells me that she is telling the worst of it. At this point it’s just gut instinct here and not the first time I’ve held thru PK issues before. $PRVB had some as well before they got FDA approval. We can afford to have 50 patients removed from the trial and still be powered for success. These 3rd party CRO’s need to do better

User Image DrScoob Posted - 1 month ago

$PRVB Still bagholding

User Image mlover Posted - 1 month ago

@glimdbea Hello, Dr. Thank you again for teaching me easily. $PRVB also had the same process toward final BO. Fear of market decline after approval VS The first treatment.

User Image Jwa68 Posted - 01/31/24

@StellarTrida @monterocky848 In time, yes, that is what I personally believe. Much like I predicted $PRVB previously. Just my opinion, Do your own dd and I think you will see many reasons for my expectation.

User Image billymike Posted - 1 month ago

@Jwa68 check out $PDSB might be $PRVB situation.

User Image billymike Posted - 1 month ago

$PDSB @Jwa68 have you looked into this company maybe another $PRVB situation.

User Image BigElvis_GTown Posted - 2 months ago

@Old_and_Broke_Nicholson I remember 7 and thinking it would be nice to hit 9. I can wait. Same situation with $PRVB then boom it happened. 11k shares from 4 to 25. Lots of ups and downs in between and patience

User Image Bigprofits23 Posted - 2 months ago

@Bamabeast256 If there was evidence it would be illegal, right? I have been involved in 2 BO’s over the last 15 months. $MYOV & $PRVB ARDX seems to have the best management team out of the 3. That would be the only reason I would say NA to a BO unless it was relatively high. But as I SPECULATE the previous BO’s were $27 & $25 respectively. GL!

User Image WallStreetBuyDip Posted - 2 months ago

How do you make your trade? Will next trade $PRVB + $AUPH when H% is low. My summary for Small + Mid cap stocks. I ONLY buy when heaviness % is low. The result speaks for itself. Got timestamps for the skeptics. It's a simple strategy. Learn what "heaviness %" by Algos.

User Image paynespleasurepalace Posted - 2 months ago

@CC1975 explaining shit to u gets tiring. Whats the point? I've seen this before. Most recent example is $prvb. Check out what happened to them after approval. Or don't. Idgaf if u believe it or not. Gotta block ur bitch ass because u cant stop dick riding. Get the dicks out ur mouth dummy.

User Image Jwa68 Posted - 2 months ago

@TreeLineViews I meant to say $PRVB. My apologies.

User Image WallStreetBuyDip Posted - 2 months ago

How do you make your trade? Will next trade $PRVB + $AUPH when H% is low. My summary for Small + Mid cap stocks. I ONLY buy when heaviness % is low. The result speaks for itself. Got timestamps for the skeptics. It's a simple strategy. Learn what "heaviness %" by Algos.

User Image wyoming2020 Posted - 2 months ago

$PDSB $PRVB came out of blue after FDA phase 3, we have some more road ahead here. Lots of competition but I am personally optimistic

User Image WallStreetBuyDip Posted - 2 months ago

How do you make your trade? Will next trade $PRVB + $AUPH when H% is low. My summary for Small + Mid cap stocks. I ONLY buy when heaviness % is low. The result speaks for itself. Got timestamps for the skeptics. It's a simple strategy. Learn what "heaviness %" by Algos.

User Image Magnificient Posted - 2 months ago

$AUPH $PRVB hey where are the desperate fake bulls like me now? Haaaa Yesterday they would accept a offer of 16. Today nothing under 25??

User Image JAH1 Posted - 2 months ago

$TLSA https://www.yalemedicine.org/news/teplizumab-new-diabetes-drug#:~:text=How%20does%20this%20new%20diabetes,Herold%20explains. Some background on why Foralumab works in T2D. Teplizumab is the drug $PRVB sold back in February for 2.9bn

User Image Magnificient Posted - 2 months ago

$AUPH this is depressing like $PRVB before bo. I was so happy after bo annoucement, same day i visited Happy Pink Panda China Massage Institute, booked a 2 hours 5 hands Massage for celebration. Sorry im trying to be funny but my mood is

Analyst Ratings
HC Wainwright & Co. Neutral Mar 15, 23
SMBC Nikko Neutral Mar 14, 23
Jefferies Hold Mar 14, 23
Chardan Capital Buy Mar 13, 23
HC Wainwright & Co. Buy Feb 15, 23
SVB Leerink Outperform Nov 21, 22
Chardan Capital Buy Nov 21, 22
Oppenheimer Outperform Nov 18, 22
Jefferies Buy Nov 18, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Sessa Capital (Master), L.P. 10% Owner 10% Owner Apr 14 Sell 24.32 2,190,549 53,274,152 15,567,497 04/18/23
Leon Francisco Chief Scientific Off.. Chief Scientific Officer Feb 10 Sell 10.08 75,985 765,929 1,573,000 02/14/23
Leon Francisco Chief Scientific Off.. Chief Scientific Officer Feb 10 Option 2.5 75,985 189,962 1,598,985 02/14/23
Hoitt Jason Chief Commercial Off.. Chief Commercial Officer Feb 10 Sell 10.0012 4,500 45,005 02/14/23
Palmer Ashleigh Director and CEO Director and CEO Feb 10 Sell 10.08 75,835 764,417 2,570,050 02/14/23
Palmer Ashleigh Director and CEO Director and CEO Feb 10 Option 2.5 75,835 189,588 2,595,885 02/14/23
Palmer Ashleigh Director and CEO Director and CEO Jan 18 Sell 10.27 24,165 248,175 2,570,050 01/20/23
Palmer Ashleigh Director and CEO Director and CEO Jan 18 Option 2.5 24,165 60,412 2,594,215 01/20/23
Leon Francisco Chief Scientific Off.. Chief Scientific Officer Jan 18 Sell 10.27 24,015 246,634 1,573,000 01/20/23
Leon Francisco Chief Scientific Off.. Chief Scientific Officer Jan 18 Option 2.5 24,015 60,038 1,597,015 01/20/23
Leon Francisco Chief Scientific Off.. Chief Scientific Officer Dec 22 Sell 10 1,943 19,430 1,573,000 12/27/22
Leon Francisco Chief Scientific Off.. Chief Scientific Officer Dec 22 Option 2.5 1,943 4,858 1,573,375 12/27/22